Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Evolutec Group

Criteria

Inclusion Criteria:

• be male or female who has undergone unilateral cataract extraction by phacoemulsification (PHACO) method with implantation of a posterior chamber intraocular lens

Exclusion Criteria:

• have unstable glaucoma

• have an active bacterial and/or viral infection

• use any ocular or systemic anti-inflammatory agents within 1 week prior to enrollment and for the duration of the study.